The Cancer Vaccine collaboration with the Institute for Respiratory Health (IRH) to evaluate the in vivo
effectiveness of BARD1 peptide vaccine formulations for triggering immune response and inhibiting tumour
growth in animal models continued during the quarter, with the peptide vaccine results expected in
December 2018.
Taken from the quaterly report. I see vaccine.
Ann: Ceasing to be a substantial holder, page-161
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
47.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $52.41M | |||
| Open | High | Low | Value | Volume |
| 47.0¢ | 47.0¢ | 46.5¢ | $11.03K | 23.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5223 | 47.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.0¢ | 5342 | 1 |
View Market Depth
| Last trade - 11.30am 08/10/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |